M&A Deal Summary

Toyoda Gosei Acquires ThinkCyte

On November 28, 2023, Toyoda Gosei acquired machinery company ThinkCyte

Acquisition Highlights
  • This is Toyoda Gosei’s 1st transaction in the Machinery sector.
  • This is Toyoda Gosei’s 4th transaction in Japan.

M&A Deal Summary

Date 2023-11-28
Target ThinkCyte
Sector Machinery
Buyer(s) Toyoda Gosei
Deal Type Add-on Acquisition

Target

ThinkCyte

Tokyo, Japan
ThinkCyte is focused on developing and commercializing cell analysis and sorting technology platform using AI-based cell image analysis. Its technology to analyze individual cells and sort them will enable faster and more accurate diagnoses than conventional methods. ThinkCyte was formed in 2016 and is based in Tokyo.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Toyoda Gosei

Kiyosu, Japan

Category Company
Founded 1949
Sector Automotive
Employees39,192
Revenue 1.06T JPY (2025)
DESCRIPTION

Toyoda Gosei is a specialty manufacturer of rubber and plastic automotive parts. Toyoda Gosei was founded in 1949 and is based in Kiyosu, Japan.


DEAL STATS #
Overall 4 of 13
Sector: Machinery M&A 1 of 1
Type: Add-on Acquisition M&A Deals 3 of 4
Country: Japan M&A 4 of 13
Year: 2023 M&A 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-09-26 Pyrenee

Tokyo, Japan

Pyrenee is focused on developing safe driving assistance devices to achieve safer mobility in society. Pyrenee Drive, developed by the company is a retrofit device that assists the cognitive aspect of safe driving; it captures things around the vehicle that drivers fail to notice, which is the cause of traffic accidents in about 70% of cases.2 The device is mounted on the automobile dashboard or elsewhere in the vehicle, and detects pedestrians and other automobiles and predicts their movement with AI. Pyrenee was formed in 2016 and is based in Tokya.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-04 Craif

Tokyo, Japan

Craif develops and sells test kits that can easily and highly sensitively detect the risks of seven types of cancer, including pancreatic and lung cancer, as early as cancer stage 1. These kits comprehensively and efficiently capture and measure small microRNA molecules called miRNA2 in urine, which are generally difficult to detect. Craif is based in Tokyo.

Buy -